EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Liang Tao, Xinquan Yang, Chaodong Ge, Peng Zhang, Wenjian He, Xingbo Xu, Xin Li, Wenteng Chen, Yingying Yu, Huai Zhang, Sui-Dan Chen, Xiao-Yan Pan und 6 weitere

Cell Metabolism · 2024-10 · 36 (10) · 2190-2206.e5

DOI: 10.1016/j.cmet.2024.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2024-10. Verfasst von Liang Tao und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, …. Hauptthemen laut MEDLINE: Fatty Liver, Iron. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverIronAnimalsFemaleHumansMaleMiceMiddle AgedFerroptosisLiverMice, Inbred C57BL

Stichwörter der Autor:innen

ACSL4FOT1FerroTerminator1MASHc-MYCferroptosisiron chelatoriron metabolismliver diseaseserum ferritin

Substanzen

Iron

Autor:innen und Institutionen

  • School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China; The Second Affiliat…
  • The Second Affiliated Hospital, The First Affiliated Hospital, Institute of Translational Medicine, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangz…
  • School of Basic Medical Sciences, School of Public Health, School of Pharmaceutical Science, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
  • College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang Province, China.
  • Department of Biostatistics and Medical Record, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medi…
  • Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Förderung

  • Natural Science Foundation of Hunan Province
  • National Natural Science Foundation of China

Zitieren

APA

Tao, L., Yang, X., Ge, C., Zhang, P., He, W., Xu, X., Li, X., Chen, W., Yu, Y., Zhang, H., Chen, S. D., Pan, X. Y., Su, Y., Xu, C., Yu, Y., Zheng, M. H., Min, J., & Wang, F. (2024). Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metabolism, 36(10), 2190-2206.e5. https://doi.org/10.1016/j.cmet.2024.07.013

Vancouver

Tao L, Yang X, Ge C, Zhang P, He W, Xu X, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metabolism. 2024;36(10):2190-2206.e5. doi:10.1016/j.cmet.2024.07.013

BibTeX
@article{Tao2024,
  author = {Tao, Liang and Yang, Xinquan and Ge, Chaodong and Zhang, Peng and He, Wenjian and Xu, Xingbo and Li, Xin and Chen, Wenteng and Yu, Yingying and Zhang, Huai and Chen, Sui-Dan and Pan, Xiao-Yan and Su, Yunxing and Xu, Chengfu and Yu, Yongping and Zheng, Ming-Hua and Min, Junxia and Wang, Fudi},
  title = {Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH},
  journal = {Cell Metabolism},
  year = {2024},
  volume = {36},
  number = {10},
  pages = {2190--2206.e5},
  doi = {10.1016/j.cmet.2024.07.013}
}
Kostenlos starten →